Dr. Foss on Tipifarnib in Relapsed, Refractory, T-Cell Lymphoma

By Melissa Badamo, Francine Foss, MD - Last Updated: September 27, 2024

Francine Foss, MD, of Yale School of Medicine, discusses a phase II trial of the farnesyltransferase inhibitor tipifarnib for relapsed or refractory peripheral T-cell lymphoma published in Blood Advances.

Advertisement

The overall response rate was 40% and most patients responded within four months of treatment. The median duration of response was 3.7 months. Adverse events included cytopenias and bone marrow suppression.

“Tipifarnib was a very active drug in this study, even in patients with multiply refractory T-cell lymphoma,” Dr. Foss explained. “The drug is more active in the follicular helper subtype angioimmunoblastic T-cell lymphomas.”

Advertisement
Advertisement
Advertisement
Editorial Board